BridgeBio Pharma BBIO 深 滬
等待開盤 03-26 09:30:00 美东时间
71.61
+3.080
+4.49%
華盛通- 最 高72.275
- 今 開69.29
- 成交量 126.13万股
- 最 低 68.935
- 昨 收 68.53
- 總市值 138.83亿
- 52周最高 84.94
- 市盈率 靜 --
- 換手率 0.65%
- 52周最低 28.325
- 委 比 64.26%
- 總股本 1.94亿
- 歷史最高 84.94
- 量 比 0.75
- 振 幅 4.87%
- 歷史最低 4.98
- 每 手 1
- 風險率 15.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $106
Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $91 to $106.
03-19 01:52
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
BridgeBio Oncology Therapeutics (BBOT) will present two studies at the AACR Annual Meeting 2026 in San Diego. The first, titled "The RAS:PI3Kα breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2+ models through non-canonical RAS signaling blockade," will be an oral presentation by Dr. James Stice on April 21. The second, "BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS (ON) and (OFF) inhibitor," is a poster ...
03-18 20:05
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory filings and potential commercial launches.
03-11 02:49
William Blair Initiates Coverage On BridgeBio Pharma with Outperform Rating
William Blair analyst John Boylan initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Outperform rating.
03-10 21:51
HC Wainwright & Co. Maintains Buy on BridgeBio Oncology, Raises Price Target to $29
HC Wainwright & Co. analyst Robert Burns maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and raises the price target from $27 to $29.
03-06 20:13
BridgeBio Oncology Therapeutics, Inc. GAAP EPS of -$0.49
BridgeBio Oncology Therapeutics, Inc. press release (BBOT): GAAP EPS of -$0.49. Cash Position: As of December 31, 2025, BBOT had cash, cash equivalents and marketable securities totaling $425.5 millio...
03-06 06:59
BridgeBio Oncology Q4 EPS $(0.49) Beats $(0.56) Estimate
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.56) by 13.12 percent.
03-06 05:10
